Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer

AstraZeneca100 enrolled

Overview

The purpose of this study is to characterize the demographic and clinical aspects, and describe the frequency and type of KRAS mutation in a Brazilian population sample with advanced non-small cell lung cancer (NSCLC).

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Non Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histological or cytological confirmation of locally advanced or metastatic Non Small Cell Lung Cancer (IIIB-IV) * Tumour sample (block of slides) available for KRAS analysis Exclusion Criteria: * Confirmation of locally advanced or metastatic NSCLC (IIIB-IV) exclusively by cytology, with no tumour sample access. * Previous treatment using a MEK inhibitor or any other regimen containing docetaxel (previous treatment with paclitaxel is accepted)

Locations (5)

Research Site

Belo Horizonte, Brazil

Research Site

Porto Alegre, Brazil

Research Site

Rio de Janeiro, Brazil

Research Site

Santo André, Brazil

Research Site

São Paulo, Brazil

Outcomes

Primary Outcomes

To analyze the frequency and type of KRAS mutation in a sample of the Brazilian population with advanced NSCLC.

Time frame: March 31, 2010

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.